Vaxcyte, Inc. — Director's Dealing 2024

Jun 21, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-06-18

Reporting Person: GUGGENHIME ANDREW (PRESIDENT AND CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-06-18	Common Stock	M	8000	$5.35	Acquired	104720	Direct
2024-06-18	Common Stock	S	7652	$71.893	Disposed	97068	Direct
2024-06-18	Common Stock	S	348	$72.556	Disposed	96720	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-06-18	Stock Option (right to buy)	$5.35	M	8000	Disposed	2030-05-11	Common Stock (8000)	Direct

Footnotes

F1: Includes 1,041 shares acquired under the Issuer's Employee Stock Purchase Plan on May 17, 2024.

F2: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $71.415 to $72.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.48 to $72.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter.